Form 4: Blueprint Medicines Executive Philina Lee Reports Stock Transactions

Philina Lee, Chief Commercial Officer of Blueprint Medicines, reports the acquisition and disposal of company stock on March 13, 2024.

Summary

• On March 13, 2024, Philina Lee, Chief Commercial Officer of Blueprint Medicines, reported transactions involving the company's common stock.
• Lee acquired 523 shares at $8.8 and 1,224 shares at $15.01.
• Lee also disposed of 6,223 shares at a weighted average price of $90.55 and 1,800 shares at a weighted average price of $89.88.
• Following these transactions, Lee directly owns 34,729 shares of Blueprint Medicines common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which is important for maintaining market confidence.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice across publicly traded companies.
• These filings are publicly available and are used by investors to gauge sentiment and potential future performance.
• Comparing Lee's transactions to those of other executives in similar biotech companies could provide further insights, but that data is not available in this document.

Stakeholder Impact

• The reported transactions may influence investor perception of Blueprint Medicines.
• Transparency in insider trading activity helps maintain investor confidence.

Key Dates